Bristol-Myers Squibb to acquire IFM Therapeutics for $300+ million
Staff Writer |
Bristol-Myers Squibb Company will acquire all of the outstanding capital stock of IFM Therapeutics.
Article continues below
IFM Therapeutics is a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.
The acquisition will give Bristol-Myers Squibb full rights to IFM’s preclinical STING (stimulator of interferon genes)and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.
This is is an example of Bristol-Myers Squibb’s continued focus on leveraging external innovation to expand and develop its portfolio of transformative medicines.
IFM’s STING agonist program includes a lead asset that accelerates the company’s efforts against this target, while the NLRP3 agonist program includes a potential first-in-class pipeline candidate.
Under the terms of the agreement, Bristol-Myers Squibb will pay $300 million upon closing of the transaction.
IFM stockholders also will be entitled to additional contingent payments of up to $1.01 billion for each of the first products from the two programs upon the achievement of certain development, regulatory and sales milestones.
Also, IFM is eligible for additional contingent milestone payments for further products resulting from these programs.
In connection with the acquisition, a newly formed entity will be established by the current shareholders of IFM - IFM Therapeutics LLC – and it will retain IFM’s current personnel and facilities, as well as its remaining research programs, which include an NLRP3 antagonist program focused on curbing immune responses that lead to inflammatory diseases and fibrosis.
In consideration of an additional payment at closing and future investment, Bristol-Myers Squibb will be granted at closing certain rights against the newly formed entity’s NLRP3 antagonist program, including a right of first refusal.
The transaction has been approved by the boards of directors of both companies and by the stockholders of IFM.
Bristol-Myers Squibb and IFM anticipate the transaction will close during the third quarter of 2017.
Closing of the transaction is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. ■